BioCentury | Nov 21, 2019
Tools & Techniques

Measuring real-time PK/PD by monitoring aberrant chaperone activity

...and forms an “epichaperome.” For proof of concept, her team generated a radiolabeled version of Samus Therapeutics Inc.’s...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...affairs at TG Therapeutics Inc. (NASDAQ:TGTX) and Morgan was chief regulatory/quality and contracting officer of Samus Therapeutics Inc....
BioCentury | Oct 25, 2018
Distillery Therapeutics

Autoimmune disease

...vehicle. Next steps could include optimizing and testing the inhibitor in additional models of UC. Samus Therapeutics Inc....
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...against apoptosis. Next steps could include evaluating the selective Hsp90 inhibitor in animal cancer models. Samus Therapeutics...
...Published online Oct. 3, 2013 Patent application filed covering purine-scaffold Hsp90 inhibitors; PU-H71 licensed to Samus Therapeutics...
BioCentury | Jan 12, 2012
Strategy

A conversation with Laurie Glimcher

...2011 PxRadia Inc. Scottsdale, Ariz. Anti-ceramide antibody for GI syndrome and other inflammatory conditions 2011 Samus Therapeutics...
Items per page:
1 - 5 of 5
BioCentury | Nov 21, 2019
Tools & Techniques

Measuring real-time PK/PD by monitoring aberrant chaperone activity

...and forms an “epichaperome.” For proof of concept, her team generated a radiolabeled version of Samus Therapeutics Inc.’s...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...affairs at TG Therapeutics Inc. (NASDAQ:TGTX) and Morgan was chief regulatory/quality and contracting officer of Samus Therapeutics Inc....
BioCentury | Oct 25, 2018
Distillery Therapeutics

Autoimmune disease

...vehicle. Next steps could include optimizing and testing the inhibitor in additional models of UC. Samus Therapeutics Inc....
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...against apoptosis. Next steps could include evaluating the selective Hsp90 inhibitor in animal cancer models. Samus Therapeutics...
...Published online Oct. 3, 2013 Patent application filed covering purine-scaffold Hsp90 inhibitors; PU-H71 licensed to Samus Therapeutics...
BioCentury | Jan 12, 2012
Strategy

A conversation with Laurie Glimcher

...2011 PxRadia Inc. Scottsdale, Ariz. Anti-ceramide antibody for GI syndrome and other inflammatory conditions 2011 Samus Therapeutics...
Items per page:
1 - 5 of 5